Global Lupus Competitor Landscape 2018: Market Entry & Direction of Travel Positioning Analysis for Pipeline & Currently Approved Therapies

News provided by

Jan 25, 2019, 18:15 ET

DUBLIN, Jan. 25, 2019 /PRNewswire/ --

The "Competitor Landscape: Lupus" report has been added to ResearchAndMarkets.com's offering.

"Competitor Landscape: Lupus", briefings contain evaluations of ongoing development activities within the market, together with analysis of current & potential future product positioning.

Key Highlights from the report

Registration of a Phase III AURORA2 long-term extension study indicates efforts by Aurinia to gather additional safety data for voclosporin.
GSK is currently the only company conducting pediatric SLE trials, which could provide a significant point of differentiation for belimumab vs. novel competitors, if successful.
Inclusion of SRI-4 as a primary endpoint as opposed to SLEDAI-2K (primary endpoint used in baricitinib's Phase II SLE trial) is in line with competitors such as belimumab, and could allow physicians to draw indirect comparisons between therapies even in the absence of H2H trials.

The report includes four key sections

Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma's view of the lupus market landscape

Landscape Updates: Section contains the following analysis

Order of Entry' analysis, containing detailed timeline forecasts for each drug in Phase II development or higher, and timeline forecasts for each approved product's lifecycle management initiatives
Direction of Travel' analysis for currently approved therapies, together with an assessment of initial market entry strategies for key pipeline candidates

Approved & Pipeline Product Landscape: Section contains the following analysis

An overview of pipeline & approved products, containing snapshots of current development status

Appendix: Contains the following information

US & EU label information for marketed products (i.e. GSK's Benlysta).
Current Early Stage Lupus Pipeline & candidate Watch List'.
Timeline Assumptions, including standard assumptions + drug-specific assumptions.

Scope

The briefing is based on Sociable Pharma's analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
Market Entry' & Direction of Travel' positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to Buy

Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Key Topics Covered:

Introduction to Sociable Pharma's Lupus Competitor Landscape'
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Direction of Travel' & Market Entry Strategies
Pipeline & Approved Product Landscape
Overview: Pipeline & Approved Biologics & Small Molecules
Appendix

Companies Mentioned

AbbVie
Ablynx
ACEA Biosciences
Amgen
Anthera
Apellis Pharmaceuticals
Astellas
AstraZeneca
Aurinia Pharma
Baxalta
Biogen
Biogen
Biotest
BMS
Boehringer Ingelheim
Boston Pharmaceuticals
Celgene
Chi-Med
Corbus Pharma
Corestem
EMD Serono
Galapagos
Genentech
Gilead
GlaxoSmithKline
Idera Pharmaceuticals
Idorsia
Iltoo Pharma
Immunomedics
ImmuPharma
Imperial College London
Innocare Pharma
Invion
Janssen
Kezar Life Sciences
Lilly
MacroGenics
MedImmune LLC
Mitsubishi Tanabe
Nektar Therapeutics
Neovacs
Novartis
Omeros Corporation
Pfizer
Ra Pharmaceuticals
RemeGen
Resolve Therapeutics
Roche
Sanofi
Seattle Genetics
Shire
Takeda
Theramab
UCB
Xencor
XTL Biopharma

For more information about this report visit https://www.researchandmarkets.com/research/q4g226/global_lupus?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links